Unknown

Dataset Information

0

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.


ABSTRACT: UNLABELLED:Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to the EGFR inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EGFR EC mutations display EGFR addiction. In contrast to KD mutants found in lung cancer, glioma-specific EGFR EC mutants are poorly inhibited by EGFR inhibitors that target the active kinase conformation (e.g., erlotinib). Inhibitors that bind to the inactive EGFR conformation, however, potently inhibit EGFR EC mutants and induce cell death in EGFR-mutant GBM cells. Our results provide first evidence for single kinase addiction in GBM and suggest that the disappointing clinical activity of first-generation EGFR inhibitors in GBM versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these 2 cancer types. SIGNIFICANCE:Approximately 40% of human glioblastomas harbor oncogenic EGFR alterations, but attempts to therapeutically target EGFR with first-generation EGFR kinase inhibitors have failed. Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain.

SUBMITTER: Vivanco I 

PROVIDER: S-EPMC3354723 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco Igor I   Robins H Ian HI   Rohle Daniel D   Campos Carl C   Grommes Christian C   Nghiemphu Phioanh Leia PL   Kubek Sara S   Oldrini Barbara B   Chheda Milan G MG   Yannuzzi Nicolas N   Tao Hui H   Zhu Shaojun S   Iwanami Akio A   Kuga Daisuke D   Dang Julie J   Pedraza Alicia A   Brennan Cameron W CW   Heguy Adriana A   Liau Linda M LM   Lieberman Frank F   Yung W K Alfred WK   Gilbert Mark R MR   Reardon David A DA   Drappatz Jan J   Wen Patrick Y PY   Lamborn Kathleen R KR   Chang Susan M SM   Prados Michael D MD   Fine Howard A HA   Horvath Steve S   Wu Nian N   Lassman Andrew B AB   DeAngelis Lisa M LM   Yong William H WH   Kuhn John G JG   Mischel Paul S PS   Mehta Minesh P MP   Cloughesy Timothy F TF   Mellinghoff Ingo K IK  

Cancer discovery 20120331 5


<h4>Unlabelled</h4>Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to the EGFR inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EGFR EC mutations display EGFR addiction. In contrast to KD mutants found in lung cancer, glioma-specific EGFR EC mutants are poorly inhibited by EGFR inhibitors that targe  ...[more]

Similar Datasets

| S-EPMC5355235 | biostudies-literature
| S-EPMC3186869 | biostudies-literature
| S-EPMC7055889 | biostudies-literature
| S-EPMC4922765 | biostudies-literature
| S-EPMC8018319 | biostudies-literature
| S-EPMC8490392 | biostudies-literature
| S-EPMC5593363 | biostudies-other
| S-EPMC3203921 | biostudies-literature
| S-EPMC9679652 | biostudies-literature
| S-EPMC4085484 | biostudies-literature